BRAF^V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist

This article is co-authored by a patient with BRAF^V600E metastatic melanoma and his treating oncologist.

The patient describes how he coped with his diagnosis and treatment. He details the pathway of his melanoma treatment, which has spanned over 10 years, including surgical interventions, medical treatment, and participation in clinical trials. He relates his experience of living with the disease-and the adverse effects of treatment-in the long term. The clinical perspective of his treating oncologist reviews the diagnostic process and explains how the therapeutic options were selected for and with the patient. The oncologist also addresses the integration of the patient into clinical trials involving programmed death-1 (PD-1) inhibitors and BRAF/MEK inhibitors. Challenges related to the adverse effects that occurred and the personalised treatment of the patient are also discussed. Finally, the article evaluates current advances in treatment and future therapeutic approaches.

This case highlights the challenges of identifying which therapeutic options are most appropriate for individual patients with BRAF^V600E metastatic melanoma.